Medtronic, a global leader in healthcare technology, announced that it has entered into an agreement with Retia Medical, an innovative digital health company that develops advanced hemodynamic solutions, to distribute the Argos™ cardiac output monitor. The Argos™ monitor provides healthcare professionals with accurate hemodynamic data to support the treatment of high-risk surgical and critically ill patients. The Argos™ monitor is now available in the U.S. exclusively from Medtronic. Financial terms of the agreement were not disclosed.

In the operating room (OR) and critical care units, circulatory shock, often manifested as hypotension, is a primary cause of complications and requires intervention within minutes to prevent damage to vital organs. Hemodynamic monitoring detects important changes in a patient’s hemodynamic status, enabling clinicians to intervene earlier ensuring sufficient oxygen delivery and preserving end organ function.

“Studies have shown that patients had 1 to 2-day shorter stays in the ICU when preemptive hemodynamic intervention was used,”¹ said Blake Tatum, U.S. commercial vice president of the Acute Care & Monitoring business, which is part of the Medical Surgical portfolio at Medtronic. "The Argos™ cardiac output monitor complements our INVOS™ cerebral oximetry technology to help provide clinicians with comprehensive insights into a patient’s status in both the operating room and intensive care unit. By integrating this technology into our Acute Care & Monitoring portfolio, we are advancing our commitment to delivering actionable insights that enable clinicians to personalize care and improve outcomes for critically ill patients.”

The Argos™ cardiac output monitor offers an advanced algorithm called Multi-Beat Analysis™ (MBA™), developed at the Massachusetts Institute of Technology (MIT) and Michigan State University. Unlike other monitors that analyze only one beat at a time, the MBA™ algorithm analyzes multiple heartbeats from the blood pressure signal to model a patient’s vascular resistance directly. It provides accurate hemodynamic data on ten comprehensive parameters even during changes in vasomotor tone, low cardiac output, and arrhythmia.³

“Medtronic is the ideal partner for Retia Medical as we expand the reach of the Argos™ cardiac output monitor,” said Marc Zemel, chief executive officer of Retia Medical. “Their robust portfolio, strong customer relationships, and leadership in advancing acute care and monitoring technologies uniquely position them to deliver the benefits of our innovative solution to clinicians and patients in the U.S. We are excited to partner with Medtronic to set a new standard in hemodynamic monitoring.”

The Argos™ cardiac output monitor leverages the patient’s existing arterial line using a single reusable cable to connect the monitor to a radial blood pressure transducer. The monitor requires no calibration, features an intuitive multi-touch screen interface, and can be fully operational in minutes. Training can be completed in less than five minutes. In addition, there is no need for costly disposable accessories to connect. For more information about the Argos™ cardiac output monitor visit medtronic.com/argos.

About Retia Medical
Headquartered in White Plains, NY, Retia Medical Systems, Inc. is a venture-backed developer and provider of advanced algorithms including AI-based approaches for patient monitoring and management. Retia’s mission is to provide accurate data and insights to aid surveillance, diagnosis and management of high-risk surgical and critically ill patients to improve outcomes. Retia Medical’s Argos™ Monitor, with its Multi-Beat Analysis (MBA®) algorithm, provides consistently accurate hemodynamic measurements for critically ill adult patients, enabling clinicians to make more informed, data-driven decisions to improve end-organ function. Additionally, the Argos™ system is unique in its class by not requiring costly disposables to monitor each patient. The Argos™ uses a single cable connection and takes less than 1 minute to start monitoring. Learn more at www.retiamedical.com and follow us on LinkedIn Retia Medical.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Argos™ cardiac output monitor is manufactured by Retia Medical and distributed by Medtronic.

Patient Monitoring products should not be used as the sole basis for diagnosis or therapy and are intended only as an adjunct in patient assessment.

Argos, Multi-Beat Analysis, and MBA are trademarks or registered trademarks of Retia Medical Systems, Inc.

References:

1. Benes J, Giglio M, Brienza N, Michard F. The effects of goal-directed fluid therapy based on dynamic parameters on post-surgical outcome: a meta-analysis of randomized controlled trials. Crit Care. 2014;18(5):584. Published 2014 Oct 28. doi:10.1186/s13054-014-0584-z
2. Redfors B, Watson BM, McAndrew T, et al. Mortality, Length of Stay, and Cost Implications of Procedural Bleeding After Percutaneous Interventions Using Large-Bore Catheters. JAMA Cardiol. 2017;2(7):798-802. doi:10.1001/jamacardio.2017.0265
3. Kee A, Kirchhoff B, Grigsby J, et al. Prospective Evaluation of a Multibeat Analysis Cardiac Index Estimation in Patients With Cardiogenic Shock. J Cardiothorac Vasc Anesth. 2023;37(8):1377-1381. doi:10.1053/j.jvca.2023.04.003

Contacts:
Pamela Lee
Communications
+1-303-218-8264

Ryan Weispfenning
Investor Relations
+1-763-505-4626